CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES

For therapeutic monoclonal antibodies exhibiting nonlinear pharmacokinetic/dynamic properties, a doubling of dose may not result in a proportional change in efficacy or duration of effect. Evolocumab, a human monoclonal antibody against PCSK9, demonstrated significant and stable LDL-C reduction when